Boston-based biopharmaceutical service Parexel International Corporation announced a slew of new products that will be built on its Perceptive Cloud platform. The company said that one of the new technologies uses Microsoft’s Azure App Services and will be able to send patient data to healthcare teams and first line clinicians, alerting the them when there is a patient safety threat.
The company has also expanded some of its technology platforms. For instance, its patient can now connect with more medical devices such as the company’s own data capture technology, DataLabs, and ClinPhone. The company said its sensor will use AI to predict help predict patient adherence in trials and transfer data, reports MobiHealthNews.
“Technology has made it possible to access more meaningful data than ever before, while improving the patient experience. The challenge is in collecting that data in a way that is efficient for the patient, site, and investigator,” said Douglas Barta, CIO at Parexel. “Parexel has always been committed to helping our clients solve their most difficult challenges and applying both our innovative technology development and strategic alliance capabilities to provide seamless, patient-centric solutions to benefit our customers and their patients.”
There’s a growing trend among digital technologies to enter the life science space. Just last week, Researchably, a new startup that was born in UC Berkeley, announced its collaboration with Sanofi in China for a pilot program to use Artificial Intelligence to analyze thousands of studies and pick the ones that are most relevant to pharma stakeholders.
According to the MobiHealhNews report, Parexel’s new systems have been developed with the intention of better facilitating communication during clinical trials. The platform that will use Microsoft’s Azure App was constructed to particularly mitigate patient risks and reduce the chance of patient deaths, the company said.
As for the wearables and mobile technology, Parexel plans to use these to improve the speed and efficiency of clinical trials.
PAREXEL International Corporation is the world’s leading innovator of biopharmaceutical services. The company focuses on simplifying their clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world.